期刊文献+

猪血清白蛋白基因的克隆与序列分析 被引量:2

Cloning and Sequence Analysis of Porcine Serum Albumin Gene
下载PDF
导出
摘要 血清白蛋白融合技术是一种开发长效重组蛋白药物的新技术。为了获得猪血清白蛋白(PSA)基因,根据GenBank(登录号:AY663543)中PSA的基因序列,设计一对引物,采用RT-PCR从新鲜猪肝组织中扩增出PSA基因的全长cDNA,产物纯化后连接至pBS-T载体,转化大肠埃希菌TG1,采用PCR法及酶切鉴定法筛选出阳性菌株后进行测序。序列分析结果表明,成功克隆了PSA基因的1 821 bp全长cDNA,与GenBank中参照基因序列同源性为99.6%,氨基酸序列同源性为99.5%。本研究数据已提交至GenBank,并申请到一个登录号EF202601。 Albumin fusion technology was a novel technology utilized to develop long-acting biologics. According to the cDNA sequence of PSA (porcine serum albumin) derived from GenBank (Accession No. AY663543), a pair of primers were designed. Porcine RNA was isolated from porcine liver cells and the cDNA coding PSA was amplified by RT-PCR subsequently. The DNA fragment was cloned into vector pBS-T and transformed into E. coli TG1. After identified by both PCR and restrictive endonuclease digestion, the positive recombinant plasmid was sent for sequencing. The sequencing result suggested that the coding PSA gene was composed of 1 821 bp. The nucleotide sequences and the deduced amino sequences of PSA-T were compared with PSA. The nucleotide homology between them was 99.6 %, the amino acid homology was 99.5%. The research data had been submitted to GenBank and gained a new Accession No. EF202601.
出处 《动物医学进展》 CSCD 2007年第3期33-36,共4页 Progress In Veterinary Medicine
关键词 猪血清白蛋白 融合技术 序列分析 porcine serum albumin fusion technology sequene analysis
  • 相关文献

参考文献8

二级参考文献70

  • 1曹瑞兵,包晶晶,周海霞,郑其升,周斌,陈溥言.猪β-干扰素的原核表达及其对猪流行性腹泻病毒的抑制作用研究[J].中国病毒学,2004,19(4):364-368. 被引量:16
  • 2黄海,谢蓓,于瑞嵩,刘惠莉,张德福,曹祥荣,李震.猪IFNα基因在毕赤酵母中的高效分泌表达[J].遗传,2005,27(2):215-220. 被引量:12
  • 3郑新民,苟德明,魏庆信,华文君.人血清白蛋白DNA片段的扩增及克隆[J].湖北畜牧兽医,1997,18(1):3-7. 被引量:1
  • 4Elliott S, Egrie J, Browne J, et al. Control of rHuEPO biological activity: The role of carbohydrate. Experimental Hematology, 2004, 32 (12) :1146 - 1155.
  • 5Derek Macmillan. Selective in vitro glycosylation of recombinant proteins: semi-synthesis of novel homogeneous glycoforms of human erythropoietin. Chemistry & Biology, 2001,8 (2) :133- 145.
  • 6Sinclair A M, Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci, 2005, 94 (8) :1626 - 1635.
  • 7Glaspy J. Phase Ⅲ clinical trials with darbepoetin: implications for clinicians. Best Pract Res Clin Haematol, 2005, 18 (3) :4O7 -416.
  • 8Dunn C J, Plosker G L, Keating G M, et al. Insulin glargine:an updated review of its use in the management of diabetes mellitus. Drugs, 2003, 63 (16) : 1743 -1778.
  • 9Scholtz H E, Pretorius S G, Wessels D H, et al.Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia,2005, 48(10) : 1988 - 1995.
  • 10Lee G K. PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. Biotechnol Bioeng,2005, 92( 1 ) :24 -34.

共引文献57

同被引文献11

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部